Table 3.
Effect of placebo supplementation on biochemical variables for T2DM patients
| Baseline (n = 50) | Final treatment (n = 50) | Difference | p value* | |
|---|---|---|---|---|
| Systolic BP (mmHg) | 130.0 (121.0–140.0) | 136.5 (127.8–143.5) | −5.0 (−13.3 to 3.0) | 0.007 |
| Diastolic BP (mmHg) | 80.0 (73.5–90.0) | 83.0 (78.0–95.0) | −0.5 (−14.0 to 5.3) | 0.044 |
| Glucose (mmol/l) | 7.59 (6.38–9.19) | 8.03 (6.38–10.51) | −0.50 (−1.60 to 0.52) | 0.058 |
| BUN (mmol/l) | 4.64 (3.57–6.07) | 4.99 (4.28–6.42) | −0.71 (−2.14 to 1.25) | 0.001 |
| CT(µmol/l) | 79.56 (70.72–88.40) | 88.40 (79.56–106.068 | −8.84 (−26.52 to 8.84) | 0.001 |
| eGFR (ml/min/1.73 m2) | 61.10 (58.57–74.12) | 57.58 (52.88–64.12) | 3.47 (2.02 to 9.52) | <0.001 |
| Total cholesterol (mmol/l) | 4.39 (3.79–5.02) | 4.59 (4.05–5.30) | −0.28 (−0.68 to 0.26) | 0.012 |
| Triglyceride (mmol/l) | 1.40 (1.01–2.28) | 1.49 (1.05–1.99) | −0.011 (−0.50 to 0.25) | 0.937 |
| HDL-C (mmol/l) | 1.42 (1.15–1.67) | 1.40 (1.17–1.68) | 0.026 (−0.285 to 0.207) | 0.549 |
| LDL-C (mmol/l) | 2.32 (1.86–2.83) | 2.17 (1.84–2.97) | 0.05 (−0.44 to 0.40) | 0.940 |
| TG/HDL-C ratio | 2.39 (1.45–4.42) | 2.04 (1.32–3.11) | 0.14 (−0.62 to 1.21) | 0.363 |
| HbA1c (mmol/mol) | 60.7 (56.3–68.3) | 63.9 (59.6–73.8) | −0.14 (−0.62 to 1.21) | 0.002 |
* Wilcoxon signed-rank tests